{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:48:04Z","timestamp":1782712084135,"version":"3.54.5"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary intraosseous adenoid cystic carcinoma (PIACC) of the mandible is an exceptionally rare malignancy. While radical surgery and radiotherapy provide locoregional control, managing distant metastases remains challenging due to the lack of standard systemic therapies and the characteristically \u201ccold\u201d immune microenvironment of adenoid cystic carcinoma (ACC). We report the case of a 62-year-old male diagnosed with PIACC of the mandible presenting with synchronous bilateral pulmonary metastases (Stage IVC). Following radical resection and adjuvant radiotherapy, the patient received first-line maintenance with oral S-1, achieving stable disease for 36 months. Upon pulmonary progression, after a brief and poorly tolerated trial of sintilimab plus S-1 and subsequent docetaxel, therapy was optimized to a metronomic combination of the PD-1 inhibitor sintilimab and oral capecitabine. This immuno-metronomic regimen achieved durable disease stabilization exceeding 47 months with minimal toxicity. Upon discontinuing immunotherapy due to financial constraints, rapid disease progression ensued, underscoring the critical role of the combination. The patient subsequently received salvage anlotinib, achieving brief stabilization, but passed away from severe pneumonia, yielding a total overall survival of 101 months (~8.4 years). This case challenges the paradigm that ACC is intrinsically refractory to immunotherapy. We hypothesize that systemic interventions, potentially including immunogenic cell death induced by intervening chemotherapy and microenvironment remodeling by fluoropyrimidines, may sensitize ACC to PD-1 blockade. While limited by the lack of archival tissue for translational validation, this hypothesis-generating case warrants further investigation into combination immunotherapy strategies for metastatic ACC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1811044","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:40:28Z","timestamp":1782711628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Long-term disease control with immunotherapy in primary mandibular adenoid cystic carcinoma presenting with pulmonary metastasis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongcheng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichen","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Heyuan Key Laboratory of Molecular Diagnosis & Disease Prevention and Treatment, Doctors Station of Guangdong Province, Heyuan People\u2019s Hospital","place":["Heyuan, Guangdong, China"]},{"name":"Department of Pathology, Heyuan People\u2019s Hospital, Guangdong Provincial People's Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixin","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People\u2019s Hospital Heyuan Hospital","place":["Heyuan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27143","article-title":"Survival and prognosis of metastatic head and neck adenoid cystic carcinoma","volume":"44","author":"Zhang","year":"2022","journal-title":"Neck"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.3390\/cancers14225698","article-title":"Approaches to the management of metastatic adenoid cystic carcinoma","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jop.70063","article-title":"Clinicopathological profile of intraosseous adenoid cystic carcinoma of the jaws: a systematic review","volume":"55","author":"Lavareze","year":"2025","journal-title":"J Oral Pathol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/2422086","article-title":"A case of primary intraosseous adenoid cystic carcinoma of the mandible","volume":"2023","author":"Sasaki","year":"2023","journal-title":"Case Rep Dentistry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/jomfp.jomfp_19_20","article-title":"Intraosseous adenoid cystic carcinoma of the mandible: a rare presentation","volume":"24","author":"Indu","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2017.01.003","article-title":"Primary intraosseous adenoid cystic carcinoma of the mandible: a comprehensive review with analysis of 2 additional cases","volume":"75","author":"Hu","year":"2017"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70245-x","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Scott","year":"2010","journal-title":"PJLO"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hed.28124","article-title":"Lenvatinib in relapsed\/metastatic adenoid cystic carcinoma: real-world data from 17 Italian centers","volume":"47","author":"Francesca","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1200\/jco.2022.40.16_suppl.6020","article-title":"A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R\/M) adenoid cystic carcinoma (ACC)","volume":"40","author":"Kang","year":"2022"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17588359211013626","DOI":"10.1177\/17588359211013626","article-title":"Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study","volume":"10","author":"Zhu","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618367","article-title":"The immune landscape of Chinese head and neck adenoid cystic carcinoma and clinical implication","volume":"12","author":"Dou","year":"2021","journal-title":"Front\u00a0Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1200\/jco.2019.37.15_suppl.6084","article-title":"A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic adenoid cystic carcinoma (R\/M ACC)","volume":"37","author":"Tchekmedyian","year":"2019"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/jco.2019.37.15_suppl.6083","article-title":"NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"14","author":"Cohen","year":"2018"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0278-2391(90)90493-l","article-title":"Central adenoid cystic carcinoma of the mandible","volume":"48","author":"Brookstone","year":"1990","journal-title":"J Oral Maxillofac Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-023-08043-4","article-title":"The clinical significance for primary tumor surgery in metastatic head and neck adenoid cystic carcinoma","volume":"280","author":"Zhang","year":"2023","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"31681","DOI":"10.18632\/oncotarget.9426","article-title":"The impact of the MYB-NFIB fusion proto-oncogene in vivo","volume":"7","author":"Mikse","year":"2016","journal-title":"KJO"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.29.24306581","article-title":"Phase II study of nivolumab and ipilimumab for treatment of metastatic\/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other Malignant salivary gland tumors","volume":"14","author":"Young Kwang","year":"2025"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell\u2013dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106065","article-title":"5\u2010Fluorouracil efficacy requires anti\u2010tumor immunity triggered by cancer\u2010cell\u2010intrinsic STING","volume":"40","author":"Tian","year":"2021","journal-title":"EMBO J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110129","article-title":"5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy\u2013resistant lung tumor","volume":"120","author":"Mathew","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/cancers12061641","article-title":"Fluoropyrimidine modulation of the anti-tumor immune response-prospects for improved colorectal cancer treatment","volume":"12","author":"Gmeiner","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12315","article-title":"Induction of immunogenic cell death of esophageal squamous cell carcinoma by 5-fluorouracil and cisplatin","volume":"35","author":"Nishimura","year":"2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13263","article-title":"Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: from basic science to clinical application","volume":"321","author":"Ghiringhelli","year":"2024","journal-title":"JIR"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202408.0349.v1","article-title":"Personalized immunotherapy achieves complete response in metastatic adenoid cystic carcinoma despite lack of conventional biomarkers","volume":"31","author":"Tokat","year":"2024","journal-title":"Curr Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2433","article-title":"Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study","volume":"11","author":"Su","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Vatche","year":"2019"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:40:38Z","timestamp":1782711638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1811044"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1811044","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1811044"}}